DUBLIN, April 25, 2014 /PRNewswire/ —
Transcriptomics refers to the structural and functional aspects of a complete set of transcripts present in an individual or group of cells. The demand for transcriptomics research is increasing due to the consistent technological upgrades in several techniques (such as polymerase chain reaction (PCR), ribonucleic acid (RNA) sequencing and microarrays, etc.) employed for transcriptome analysis.
Currently, the analysis of transcriptome of several organisms is facilitated with the help of advanced technological platforms such as next generation sequencing platforms followed by polymerase chain reaction, microarrays and gene regulation technologies. These technologies are applied in the process of drug discovery, medical research, clinical diagnosis of diseases and others. With the burgeoning demand for targeted therapeutics and continuous improvements in healthcare infrastructure, transcriptomics technologies promise lucrative commercialization prospects.
There is a demand for technology sophistication to ensure optimum results. For example, presently, there is a need for multiplexed RNA sequencing and quantagene RT-PCR which enable the sequencing and analysis of numerous transcripts and reads simultaneously. These technological sophistications in turn create a demand for effective data analysis tools and service (bioinformatics) in order to handle and manage huge amount of data from these technological platforms.
Transcriptomics technologies are applied in studying gene expression patterns, drug discovery and clinical diagnosis of disorders such as cardiovascular, central nervous system disorders, cancers and others. Transcriptome analysis tools and services are used in identification of novel gene sequences and potential drug targets.
Also, they provide insights about gene expression patterns and gene regulation mechanisms that are responsible to trigger the functioning and production of proteins. There is a lot of complexity involved in study of structural and functional aspects of complete set of transcripts present in a given cell or population of cells. Henceforth, several pharmaceutical and biotechnology companies are investing in medical research to develop robust methodologies with high efficiency and reliability.
Geographically, North America dominated the global transcriptomics technologies market in 2012 with a revenue share of over 35%. The presence of well equipped medical and research laboratories, increased awareness of biotechnological research and increased participation of respective governments are some of the major factors responsible for region’s leadership position.
For more information visit http://www.researchandmarkets.com/research/3mc4j9/transcriptomics
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets